IDEAYA Biosciences, Inc.
IDYA
$33.09
$0.260.79%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 3,024.43% | 5,377.66% | -41.47% | -54.85% | -70.07% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3,024.43% | 5,377.66% | -41.47% | -54.85% | -70.07% |
| Cost of Revenue | 6.80% | 90.57% | 101.67% | 123.43% | 127.53% |
| Gross Profit | 66.63% | 18.95% | -112.51% | -144.87% | -171.07% |
| SG&A Expenses | 61.11% | 56.50% | 45.44% | 47.57% | 38.84% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.19% | 85.29% | 92.39% | 110.31% | 111.62% |
| Operating Income | 51.28% | 7.06% | -100.76% | -126.39% | -143.23% |
| Income Before Tax | 58.58% | 9.76% | -115.82% | -138.25% | -142.98% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 58.58% | 9.76% | -115.82% | -138.25% | -142.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 58.58% | 9.76% | -115.82% | -138.25% | -142.98% |
| EBIT | 51.28% | 7.06% | -100.76% | -126.39% | -143.23% |
| EBITDA | 51.75% | 7.19% | -102.12% | -128.50% | -145.98% |
| EPS Basic | 61.00% | 20.97% | -73.55% | -79.26% | -67.97% |
| Normalized Basic EPS | 60.75% | 15.94% | -71.80% | -76.90% | -66.50% |
| EPS Diluted | 60.37% | 20.24% | -73.55% | -79.26% | -67.97% |
| Normalized Diluted EPS | 60.26% | 15.24% | -71.80% | -76.90% | -66.50% |
| Average Basic Shares Outstanding | 8.37% | 15.83% | 25.88% | 32.44% | 42.08% |
| Average Diluted Shares Outstanding | 8.73% | 16.21% | 25.88% | 32.44% | 42.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |